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Abstract: 
Diet has been shown to be a major factor in modulating the structure of the 
mammalian gut microbiota by providing specific nutrient sources and inducing 
environmental changes  (pH, bile acids) in the gut ecosystem. Long-term dietary 
patterns and short-term interventions have been shown to induce changes in gut 
microbiota structure and function, with several studies revealing metabolic changes 
likely resulting from the host-microbiota cross-talk, which ultimately could influence 
host physiology. However, a more precise identification of the specific dietary patterns 
and food constituents that effectively modulates the gut microbiota and brings a 
predictable benefit to the host metabolic phenotype is needed to establish microbiome-
based dietary recommendations. Here we briefly review the existing data regarding gut 
microbiota changes induced by different macronutrients and the resulting metabolites 
produced via their respective fermentation, including their potential effects on obesity 
and associated metabolic disorders. We also discuss major limitations of current dietary 
intervention studies as well as future needs of applying cutting-edge ‘omic’ techniques 
and of progressing in functional microbiota gene discovery to establish robust causal 
relationships between the dietary-microbiota-induced changes and metabolic health or 
disease. 
 
 
 
 
 
 
 
	 3
Introduction: 
Recent evidence suggesting a role of intestinal dysbiosis in promoting or 
aggravating different diseases such as obesity, type 2 diabetes and inflammatory bowel 
disease (IBD) [1] has sparked a revolutionary shift in regarding the gut microbiota as a 
significant player in human health rather than just being a commensal hitchhiker. 
Components of the gut microbiota are now considered to play significant roles in areas 
as diverse as the regulation of intestinal function, metabolism, behavior, blood vessel 
formation, and immune function [2].  Many interactions of the commensal gut 
microbiota with host physiology have been defined as beneficial, such as providing 
vitamins and essential nutrients, improving the digestibility of nutrients (e.g. complex 
polysaccharides), maintaining normal gut motility and immune function and releasing 
chemicals potentially involved in cancer prevention [3-5]. In contrast, emerging 
evidence has suggested a contributory role of intestinal dysbiosis and specific microbial 
metabolic products in the development of diseases such as metabolic syndrome, 
cardiovascular diseases, IBD and some cancers. Intestinal health and its impact beyond 
the gut is now viewed as at least partially dependent on the composition and function of 
the gut microbiota and its respective metabolic products that can interact with and 
influence host physiology [3]. This concept has reinforced the necessity to identify the 
environmental factors that can modify the gut microbiota and understand how these 
changes affect the microbiota metabolic output and ultimately host physiology and 
health. 
Diet has emerged as an instrumental factor in defining and shaping the 
mammalian gut microbiota [6, 7]. Although the gut microbiota is relatively stable in 
healthy adult human populations [8], short-term alterations in diet have been 
demonstrated to rapidly change microbial composition, which can occur within 24 
	 4
hours of diet intervention [9, 10], although more profound changes could require longer 
dietary modifications [8].  Long-term dietary patterns appear to have a substantial effect 
on shaping the human gut microbiota [10], as common microbial features are observed 
in humans from geographically distinct countries with similar diets higher in plant-
derived polysaccharides (South America, Malawi, Africa/Burkina Faso) compared to 
humans from countries with typical Western diets rich in fat and protein (U.S. and 
Europe) [11, 12]. Dietary effects on human gut microbiota have also been directly 
demonstrated recently in dietary intervention studies of different durations (reviewed in 
[13]). The gut microbiota has also been demonstrated to some extent to be resilient, 
whereby microbial compositional changes in mice have been shown to revert back to 
the original structures after short dietary disturbances are removed and the animals are 
returned to the original diet [14]. Recently, however, the long-term impact on mice fed 
low-fiber diets over successive generations was shown to cause a progressive loss of 
certain fiber-fermenting bacteria that could not be restored by fiber-rich diets [15], thus 
demonstrating the potentially serious effects that sustained diets can have on modulating 
the microbiota diversity. 
The mammalian gut environment is profoundly different in distinct 
compartments traveling along the length of the gastrointestinal (GI) tract, creating 
specific environments for different species or functional bacterial assemblages. For 
instance, the small intestine has faster transit times, higher bile acid concentrations and 
greater oxygen availability than the large intestine [16], thus allowing more bile-
resistant facultative anaerobes to thrive in these areas of the gut compared to the colon. 
These differences are pronounced when comparing the proximal and distal regions of 
both the small and large intestines and also locally between the intestinal lumen and the 
mucosal surfaces [3]. Intestinal pH, which varies significantly along different regions of 
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the GI tract [17], is another critical factor in shaping bacterial species compositions and 
metabolic output [18]. Thus, environmentally diverse subcompartments within the 
human GI tract likely facilitate heterogenous bacterial assemblages, and hence accurate 
representation of the gut microbiota is largely dependent on very specific regions of the 
gut that are sampled. Since human fecal samples are largely the choice for analyzing the 
microbiota because intestinal biopsy samples are difficult or impossible to obtain, much 
of the present work characterizing the human gut microbiota is biased towards the 
community present in the lumen of the distal large intestine. Furthermore, the number of 
studies that correlated gut microbiota dietary-induced changes with their potential 
physiological and clinical consequences is very limited, thus precluding the 
understanding of their significance to human health [19].   
In this review, we analyze the existing data regarding how dietary interventions 
with different types of macronutrients (fats, carbohydrates/fibers, and proteins) affect 
the mammalian gut microbiota composition. We then discuss the metabolic intermediate 
and end products of bacterial metabolism associated with each of the three 
aforementioned macronutrients and their possible role or influence in the development 
of obesity and related metabolic disorders. Finally we discuss the future challenges 
existing in this research area and suggest potential ways to overcome these limitations. 
 
 
1. Dietary fat and high-fat diets (HFDs) 
 Ingestion of dietary fats leads to a release of digestive enzymes including lipase 
that aids in breaking down complex triacylglycerol molecules to free fatty acids and 
monoglycerides. Bile acids are released into the duodenum and associate with free fatty 
acids and monoglycerides to form micelles, which facilitate transport to the enterocyte 
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plasma membrane and eventual absorption of the freely dissolved fatty acid.  Dietary 
fatty acids are mostly absorbed and utilized in the small intestine, although a small 
percentage is able to reach the colon and can be excreted in feces [13].  
 
1.1. Lipid-degrading bacteria 
Although a large focus of study has been conducted on the relationship of the 
gut microbiota and diet-related diseases such as obesity, surprisingly little is known 
regarding dietary fat degradation in vivo within the mammalian gut, as well as the 
dominant active lipid-degrading bacterial species present in the gut. It is known that 
microbes from ruminants are able to biohydrogenate certain PUFAs such as linoleic 
acid into the saturated fatty acid stearic acid [20], and similar biotransformation of 
linoleic acid has been observed in numerous strains of human gut bacteria in vitro [21]. 
In this latter study, substantial linoleate isomerase activity was detected in the bacterial 
groups Roseburia spp., Butyrivibrio fibrisolvens and Propionibacterium freudenreichii 
subsp. shermani, and a range of metabolic products such as conjugated linoleic acids, 
vaccenic acid and hydroxy-18:1 fatty acid were detected [21]. Evidence for the ability 
of gut bacteria to metabolize dietary PUFAs in vivo was also recently demonstrated in 
mice [22, 23]. 
A great deal of work on known lipid-degrading bacteria has also been conducted 
in the biotechnology sector, with a focus on bacterial lipases for commercial enzymatic 
use.  From this work, bacterial lipases have been identified in numerous bacteria, 
including some common gut microbial genera or species: Achromobacter, 
Acinetobacter, Alcaligenes, Bacillus, Pseudomonas, Enterococcus, Lactobacillus, 
Propionibacterium, Proteus vulgaris, Staphylococcus and Serratia marcescens [24, 25]. 
However, most of these genera are not dominant members of the mammalian gut 
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microbiota, and little is known regarding degradation of lipids by the more dominant 
bacterial members.  Although not directly isolated from the gut, Čipinytė et al. [26] 
found that Enterobacter aerogenes, a common human gut bacterium, has very high 
lipase activity in vitro and is capable of degrading different types of fatty acids, ranging 
from saturated (palmitic and stearic) and unsaturated (oleic and linoleic) fatty acids to 
tryiglycerides. Theoretically, the fraction of the dietary fat that reaches the colon could 
be partially metabolized by gut bacteria although direct evidence is lacking, due to the 
fact that the main energy sources are known to be primarily carbohydrates and then 
protein products.  Although it is well-known that cholesterol is degraded by gut 
microbiota to the metabolic end product coprostanol increasing its excretion in feces 
[27], the ultimate consequences on human health are poorly understood. Further work 
on identifying lipid-degrading bacterial strains is needed in order to improve the 
existing knowledge of the microbiota’s primary role in fat metabolism. 
 
1.2. Effects of HFD on microbiota composition 
Recent observations in animal studies have found that HFDs stimulate 
substantial changes in certain taxonomic groups from the gut microbiota compared to 
control diets (Table 1). In contrast, very few controlled human interventional studies 
examining the effects of HFDs on gut microbiota composition have been carried out to 
date (Table 1). Among these human studies, Wu et al. [10] examined the changes in the 
gut microbiota of ten individuals given either a high fiber/low fat diet (LFD) or a low 
fiber/HFD and found that interindividual variation in microbial composition masked 
possible variation from short-term dietary changes. During this 10-day study, the 
enterotype identities (characterized by increased abundance of specific genera, namely 
Bacteroides and Prevotella) that were assigned to each individual remained stable 
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despite rapid changes in microbiota composition within a single day of dietary 
intervention [10]. Duncan et al. [28] also carried out a controlled human study that 
examined changes in the gut microbiota after a shift from a weight maintenance diet 
(30% of total calories from fat) to a high fat/protein, low carbohydrate diet 
(protein:carbohydrate:fat = 30%:4%:66% of total calories) labeled a HPLC diet. 
However, the primary goal of this study was to examine the effect of changing 
carbohydrates and protein content instead of fat. In fact, this study reported reductions 
in common fiber-fermenting bacteria such as Bifidobacterium, Roseburia spp. and 
Eubacterium rectale.  This trend in reduced fiber-fermenting bacteria has also been 
observed in mice subjected to HFD studies that reduced the carbohydrate (and possibly 
fiber) percentages at the expense of increasing the fat percentages in the HFDs [29].   
Other dietary factors, such as the type of fat (saturated vs. mono-unsaturated or 
PUFA), also appear to affect microbiota composition, although only a few studies have 
compared the effects of different dietary fat types. In mice, microbial diversity was 
decreased in diets high in saturated fatty acids, but not affected by diets high in PUFAs 
[30]. Saturated fat, but not PUFAs, has also been demonstrated in mice to indirectly 
lead to a ‘bloom’ of the undesired sulfite-reducing bacterium Bilophila wadsworthia via 
stimulation of taurine conjugation of hepatic bile acids, which ultimately increase 
organic sulfur availability and modulate microbiota composition [31].   
Habitual fat consumption may also affect microbiota composition, although few 
observational studies theoretically reflecting long-term dietary effects have been 
conducted.  Examination of the effects of habitual diets show that the long-term intake 
of animal fat-rich diets are associated with increases in Bacteroides [10]. Short-term 
consumption of solely animal-based diets also yielded an increase in the abundance of 
Bacteroides, as well as Alistipes and Bilophila, with a concomitant decrease in certain 
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Firmicutes groups (Roseburia, Eubacterium rectale, Ruminococcus bromii) known for 
their role in fiber fermentation [9]. 
 
1.3. Dietary fat and related effects mediated by bacterial metabolites  
 High dietary fat intake is associated with increased adiposity, chronic low-grade 
inflammation, insulin-resistance and increased bile acid production [32-35], which can 
consequentially lead to diseases such as obesity, metabolic syndrome, type 2 diabetes 
and colon cancer. However, little is known regarding potentially bioactive metabolites 
produced as a consequence of the direct or indirect effects of dietary fat on gut bacteria 
and its relationship with obesity and related metabolic alterations or symptoms. 
Haghikia et al. [36] recently discovered that long chain fatty acids (LCFAs) commonly 
found in Western diets are involved in enhancing differentiation and proliferation of T 
helper 1 (Th1) and/or Th17 cells, as well as reducing SCFAs in the gut, thus favoring a 
pro-inflammatory environment that could be adverse in obesity and its associated 
comorbidities. Furthermore, gut microbiota were found to be crucial for this observed 
effect on Th cells [36], suggesting that the primary effect on these immune cells 
possibly stems from a bacterial-related compound.  Gut microbiota have also been 
implicated in stimulating fatty acid absorption and enhancing lipid droplet formation in 
the intestinal epithelium and liver of zebrafish [37], providing a mechanistic role of gut 
microbiota in host adiposity in animal models.  Furthermore, bacteria from the phylum 
Firmicutes and their associated metabolic products were demonstrated to increase the 
number of lipid droplets while lipid droplet size was associated with other bacterial 
types [37], supporting evidence for distinct mechanisms of microbial species in 
regulating fatty acid absorption in the host. Interventions in HFD-induced obesity in 
mice with the supplementation of the bacterium Bacteroides uniformis CECT 7771 also 
	 10
showed a reduction in dietary fat absorption in enterocytes, supporting the notion that 
specific components of the human microbiota could interfere with dietary lipid 
absorption, although the mechanism or bacterial components mediating this effect were 
not investigated [38].  
 
1.4. Role of dietary fat and microbiota in inflammation 
Bacterial-induced inflammation in the host associated with obesity and type 2 
diabetes are currently thought to stem from two factors related to HF diets: increased 
lipopolysaccharide (LPS) concentration and increased permeability of the intestinal 
barrier. LPS, which is a microbial compound found in the outer membranes of Gram-
negative bacteria that can induce inflammatory responses, is largely thought to be 
responsible for the observed increase in inflammation associated with obesity and type 
2 diabetes. LPS levels are particularly associated with increased consumption of HF 
diets in mice [39] and in humans [40]. HF diets further have been linked to reduced 
intestinal barrier via direct activation of an inflammatory response by saturated fat [41]. 
Increased intestinal permeability induced by HF diets may result from decreased 
integrity of gut epithelial tight-junction proteins. In mice, reduced expression of several 
genes encoding tight (zona occludens-1 and occludin) were reduced in groups 
undergoing HFD feeding [32]. Furthermore, gut bacteria may have a role in affecting 
intestinal permeability, as antibiotic administration reduced gut permeability, systemic 
inflammation and metabolic endotoxemia [32]. Everard et al. [42] revealed that the 
abundance of the common mucus-degrading bacterium A. muciniphila actually displays 
a direct relationship with the thickness of the mucus layer, and administration of this 
bacterium to obese mice reversed HF diet-induced metabolic disorders. Activation of 
the endocannabinoid system by the gut microbiota may also contribute to increased 
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permeability of the intestinal epithelium, increased plasma LPS and inflammation, as 
well as the regulation of adipogenesis [43]. Although some correlations between 
specific gut bacterial groups and changes in intestinal barrier function have been made, 
the definitive evidence and the mechanisms associated with these changes remain to be 
clarified [44]. 
Microbial interactions with dietary lipids may also play an important role in 
inflammation in adipose tissue as well as a role in type 2 diabetes. Mice fed saturated 
fats had increased activation of Toll-like receptors (TLRs), which was at least partially 
mediated by the microbiota, leading to white adipose tissue inflammation and reduced 
insulin sensitivity [45].  This effect was not observed in mice fed unsaturated fish oil, 
suggesting that dietary fat content is instrumental in driving these microbiota-associated 
changes in inflammation.   
 
1.5. Dietary fat, microbiota and bile acids 
High dietary fat consumption is known to stimulate primary bile acid release in 
the small intestine [46]. Primary bile acids are synthesized in the liver and are 
conjugated to glycine or taurine, facilitating their uptake in the distal ileum and 
transport back to the liver. However, bacteria can deconjugate and dehydroxylate these 
primary acids in the distal ileum to prevent uptake, allowing their entry into the colon 
where they are further metabolized to secondary bile acids via the gut microbiota [1]. 
These bacterial activities may modify solubilization and absorption of dietary lipids 
throughout the intestine and increase bile fecal excretion. This, in turn, increases 
neosynthesis of additional bile acids from cholesterol in the liver, thereby regulating 
cholesterol levels via interactions with enterohepatic farnesoid X receptors [47]. 
Bacterial activities on bile acids could also affect the bile acid-induced activation of the 
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G-protein coupled membrane receptor TGR5 on enteroendocrine L cells, which leads to 
glucagon-like peptide-1 (GLP-1) secretion, an enteroendocrine peptide that regulates 
appetite, insulin sensitivity and glucose metabolism [48].  Recent work has also shown 
that bacteria from the phylum Firmicutes are primarily involved in bile acid metabolism 
in humans [49].  Secondary bile acids have been shown to alter the cecal microbiota 
composition in rats, inducing similar changes in microbiota composition to those 
induced by high-fat diets [50]. Along with fatty acids, secondary bile acids are also 
implicated in gastrointestinal cancers due to genotoxic and cytotoxic damage of cells 
[51]. Finally, bile acids have been demonstrated to select for certain groups of bacteria, 
including the sulfite-reducing bacterium B. wadsworthia described earlier. This scenario 
can lead to increased production of sulfide and ultimately increases in inflammation in 
genetically susceptible hosts [31]. 
 
 
2. Dietary fiber 
Digestion of carbohydrates is a complicated process using numerous enzymes 
and is highly dependent on the specific type of carbohydrate ingested. The majority of 
digestible dietary carbohydrates are utilized and absorbed in the small intestine, whereas 
non-digestible carbohydrates reach the colon and are fermented by anaerobic gut 
bacteria to produce a range of metabolic end products. To date, most of the studies 
investigating the role of specific nutrients on gut microbiota have been focused on the 
effects of fibers since this is the preferred carbon source for the microbiota in the large 
intestine. Nevertheless, many of the initial studies assessed the effects of fiber only in a 
limited number of bacterial groups generally considered to confer benefits for humans, 
such as Bifidobacterium or Lactobacillus species. More recent studies have now 
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revealed that specific groups of Firmicutes (mainly butyrate-producers) and 
occasionally bacterial groups from Bacteroidetes and Actinobacteria are also increased 
in response to greater fiber consumption, but specific effects largely vary depending on 
the type of fiber evaluated (Table 2) as well as on the individual’s microbiota 
composition. The following sections discuss impacts of common types of non-digestible 
carbohydrates on microbiota structure. 
 
2.1 Effects of dietary fiber on microbiota 
2.1.1. Whole grain (WG)-rich food 
WG cereals undergo minimal processing after harvesting in order to preserve the 
natural proportions of the endosperm, germ, and bran, the latter with the highest fiber 
content of all grain elements. Controlled dietary interventions on humans with WG 
cereals have reported a bifidogenic effect as well as an increase in several groups of 
Firmicutes (Blautia, Lactobacillus, butyrate-producers) and several Actinobacteria 
groups (Collinsella, Atopobium spp.) (Table 2). Interestingly, in contrast to WG wheat 
diets, Bifidobacterium was not observed to increase when subjected to wheat bran diets 
[52, 53], suggesting a high degree of specialization accordingly to the particular carbon 
sources present in the diet. The above is further exemplified with recent studies 
outlining the increase of Blautia and Roseburia species as a consequence of a dietary 
intervention with WG barley, and the increased abundance of butyrate-producers from 
Clostridium cluster IV during a dietary interventional study using WG rye [54, 55].  
 
2.1.2. Inulin, fructooligosaccharides (FOS), and galactooligosaccharides (GOS) 
Inulin is made of a heterogenous mixture of up to 60 fructose monomers with a 
terminal glucosyl moeity that can be broken down to produce shorter chain FOS (degree 
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of polymerization between two to nine).	GOS, on the other hand, are composed of 
chains of galactose units with variable chain length and types of linkages between 
monomers. These structural differences largely affect the outcome in influencing 
changes in microbiota structure [13]. Inulin, FOS and GOS all have been demonstrated 
to increase the number of Faecalibacterium prausnitzii (Table 2) detected in human 
feces [56-59]. Other well-described effects of inulin and FOS consist of elevating the 
abundance of Bifidobacterium and Lactobacillus (Table 2) with the concomitant 
improvement of certain metabolic parameters [60, 61 ]. Formula milk supplemented 
with both FOS and GOS produces a notable bifidogenic effect, causing a shift in the gut 
microbiota of formula-fed infants towards that observed for breast-fed children [62-64]. 
However, despite the recognized bifidogenic effect of fructans and galactans, this 
outcome is not always observed, and a reduction of Bacteroides, Prevotella and F. 
prausnitzii species has also been associated with FOS/inulin administration [65].  
One of the many claimed positive effects of dietary fructans and galactans is the 
ability to reduce potentially ‘undesirable’ bacterial groups that may cause detrimental 
effects to host health. For example, FOS administration has been shown to lower both 
Escherichia coli and Salmonella sp. numbers [66] while GOS reduced Clostridium 
histolyticum and Desulfovibrio abundances[67, 68]. The latter is of particular interest 
since Desulfovibrio has been linked to negative effects on human health, such as 
inducing LPS endotoxemia [69]. However, non-digestible oligosaccharides such as 
inulin have also produced opposite results in 9-12 week old pigs, as pathobionts such as 
Klebsiella spp. has been observed to use these carbon sources to proliferate [70]. 
Clearly, further studies are required to assess the potential ability of these 
oligosaccharides to shift the composition of the gut microbiota and particularly their 
health consequences. 
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2.1.3. Resistant Starch (RS) 
Non-digestible starch, known as resistant starch (RS), is assumed to have an 
extensive impact on the gut microbiota given its ability to resist degradation in earlier 
sections of the GI tract to reach distal portions of the colon. In particular, R. bromii 
seems to be a keystone species for the degradation of type RS3 in the human colon, and 
its abundance and that of closely-related species can reach proportions of 17% of the 
fecal microbiota of humans following a RS-supplemented diet [7, 71]. In addition to 
ruminococcal bacteria, other gut microbial species such as Bifidobacterium 
adolescentis, Eubacterium rectale, Prevotella spp., Parabacteroides distasonis and 
Oscillibacter relatives can be positively influenced by the intake of different types of 
RS (Table 2) [7, 72].  Similar to studies with WG supplements, variation in gut 
microbiota patterns seems to be influenced by the subtypes of the RS used [72, 73]. 
 
2.2. Dietary fiber effects on gut microbiota metabolites and host physiology 
High-fiber diets have beneficial effects on host health, including a direct impact 
on glucose and lipid metabolism by regulating nutrient absorption [74] and indirectly 
via production of SCFAs by gut microbiota fermentation. Most microbial production of 
SCFAs from carbohydrate degradation results from multiple alternative pathways 
(reviewed in [75]), which use the common glycolytic intermediate phosphoenolpyruvate 
as a substrate.  Bifidobacterium spp., on the other hand, use a unique central 
fermentative pathway called the fructose-6-phosphate shunt, or ‘bifid’ shunt, in order to 
ferment sugars to SCFAs and other organic compounds [76]. 
Predominant SCFAs produced by gut bacteria in response to fiber uptake are 
acetate, propionate, and butyrate. These SCFAs are formed primarily in the colon, in 
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which 95% are subsequently absorbed by colonocytes [77] and used as energy sources, 
being preferably used in the order butyrate > propionate > acetate [78]. Although 
butyrate is largely expended as energy by colonocytes, propionate and acetate travel to 
the liver via the portal vein, whereas acetate can reach the peripheral tissues after 
entering systemic circulation. Propionate and acetate can be used as substrates for 
gluconeogenesis and lipogenesis, whereas acetate is also a substrate for cholesterol 
biosynthesis [1, 79].  Propionate conversely inhibits cholesterol synthesis, as well as 
decreases the level of hepatic triglycerides and reduces food intake by triggering 
intracellular signaling to release anorexigenic peptides [80-82]. 
Numerous studies have attempted to correlate several different gut immune 
disorders with the reduction of SCFA availability (primarily butyrate) to colonocytes. 
Indirect evidence has shown a depletion of microbial butyrate-producers in the feces of 
patients with inflammatory bowel diseases [83-85]. Butyrate has been demonstrated to 
increase endogenous production of the glucagon-like peptide-2 (GLP-2), whose 
production may improve mucosal barrier function by increasing the rate of crypt cell 
proliferation and villus elongation, and reduce apoptosis [86-88]. Butyrate has been 
demonstrated to play a pivotal anti-inflammatory role via numerous varied mechanisms: 
by suppressing inflammatory responses at the colon by inducing Treg (regulatory T) 
cells [89], modulating the function of intestinal macrophages to down-regulate the 
production of pro-inflammatory cytokines and the TLR4 receptor [90, 91], interfering 
with differentiation and maturation of monocyte-derived dendritic cells [92], and 
activating the production of the anti-inflammatory cytokine IL-10 via binding to 
GPR109A receptors on intestinal macrophages and dendritic cells [93]. 
Butyrate and propionate have recently been demonstrated to have a protective 
role against diet-induced obesity and insulin resistance in mice [81]. The free fatty acid 
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receptors FFAR3 (GPR41) and FFAR2 (GPR43) are well known to mediate the cellular 
response to SCFAs, while the stimulation of GLP-1 by SCFAs seems to be FFAR3 
independent in mice [81]. SCFA-dependent signaling via these receptors affects 
different functions, depending on the cellular type [1]. This is in agreement with the 
differential pattern of expression described for genes encoding such receptors [94]. 
Therefore, a global model for cellular responses to SCFAs may not be possible and the 
potential pleiotropic effects must be carefully considered when proposing SCFA-based 
anti-inflammatory or anti-obesity therapies. 
Beyond characterization of cell surface receptors by which SCFAs exert their 
anti-inflammatory activity and protection against diet-related diseases, it is worth 
mentioning that different studies have been recently carried out in order to shed light on 
the intracellular molecular mechanisms driving the response to SCFAs. Particularly, 
SCFAs have been described as inhibitors of histone deacetylases (HDACs), thus 
participating in activation/repression of gene expression [95]. One example of this role 
is the SCFA-mediated differentiation of T cells into Th17, Th1, and IL-10+ Treg cells 
promoted by an attenuated HDAC activity leading to the expression of p70S6 kinase 
and activating the mTOR pathway [96]. Similarly, butyrate has been shown to have a 
protective role against type 1 diabetes in rats by altering the acetylation pattern of H3 
and H4 histones and inducing beta-cell proliferation by inhibiting the p38/ERK 
apoptotic pathway [97]. Additionally, SCFAs seem to modulate the activity of the 
peroxisome proliferator-activated receptor -dependent (PPAR), a key player to control 
adipogenesis and the fat oxidative metabolism in mitochondria. SCFAs induce lower 
expression of PPAR thus promoting activity of the uncoupling protein 2 (UCP2), 
thereby stimulating oxidative metabolism in liver and adipose tissue, insulin sensitivity, 
and weight loss [98, 99]. Although there is no direct evidence regarding the molecular 
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mechanism by which SCFAs induce down-regulation of the PPAR nuclear receptor, 
one plausible explanation can be the inhibitory role of SCFAs on HDACs given that 
these enzymes have been shown to control expression of PPAR during adipogenesis 
[100]. However, whether or not SCFAs, in particular butyrate, produced in the gut can 
reach peripheral tissues to induce such effects remains to be elucidated. 
 
 
3.  Dietary protein and high-protein diets (HPDs)  
3.1.  Fate of dietary protein and proteolytic bacteria 
Ingested dietary and endogenous protein are first digested in the small intestine 
by pancreatic enzymes and peptidases from enterocytes. A significant amount of 
oligopeptides and amino acids are then transported to the portal bloodstream via 
enterocyte transporters where they are used as amino acid precursors for protein 
synthesis or metabolized for fuels or precursors necessary for intestinal mucosal 
metabolites [101].  Typically ~10% of the ingested protein reaches the large intestine 
[13], and then undergoes further proteolysis by the colonic microbiota, yielding levels 
of some amino acids as high as millimolar concentrations as detected from human 
intestinal contents extracted from the small and large intestines [102]. Unlike 
enterocytes, colonocytes do not absorb amino acids to any significant extent and so the 
remaining amino acids in the colon are fermented by resident bacteria to a wide variety 
of metabolic products in which some metabolites can be utilized by colonocytes while 
others are excreted as waste products in feces [101]. 
Bacterial proteolytic activity in the colon has mainly been attributed to the 
genera Bacteroides, Clostridium, Propionibacterium, Fusobacterium, Streptococcus 
and Lactobacillus [103]. Other common proteolytic bacterial genera found in the human 
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gut include Peptostreptococcus, Actinomyces, Peptococcus, Ruminococcus, Bacillus, 
Staphylococcus, Megasphaera, Acidaminococcus as well as some Enterobacteria [101, 
104, 105].  As most of the work on amino acid-degrading bacterial strains has been 
carried out in the 1980’s / early 1990’s, there is a need to further examine the amino 
acid/protein-degrading capabilities of the numerous dominant anaerobic bacterial taxa 
that may not have been previously detected or cultured/isolated in these studies. 
Numerous factors affect the availability of protein in the human colon, such as 
the amount and type of protein consumed as well as the amount of undigested 
carbohydrates that reach the large intestine. As protein ingestion increases, the amount 
of residual protein entering the colon subsequently increases [106]. Since fermentable 
carbohydrates are preferentially utilized over proteins by most bacteria in the small 
intestine and proximal colon, most fermentation of amino acids as an energy source 
occurs in the distal colon, where carbohydrates are depleted [107]. However, several 
bacterial groups (Peptococcus, Acidaminococcus, and Veillonella and several strains of 
Clostridia, Fusobacterium and Eubacterium) display weak or no fermentation capacity 
of carbohydrates [108], and thus may be relatively unaffected by carbohydrate 
availability. 
 
3.2. Effects of high-protein diets (HPDs) on microbiota 
Very few studies have examined the effects of HPDs on changes in gut 
microbial composition in mammals. Among these studies, reductions in Clostridium 
coccoides, C. leptum and Faecalibacterium prausnitzii have been observed in rats 
[109], while reductions in Roseburia spp., Eubacterium rectale, Collinsella aerofaciens, 
Bacteroides spp., and Oscillibacter relatives (Table 3) have been observed in humans 
[7, 28, 110]. Unfortunately, HP diets that attempt to maintain similar caloric levels 
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between diets have similar inherent design problems as HF diets, in that the relative 
concentrations of carbohydrates and/or fats need to be reduced in order to maintain 
similar energy levels. For example, in Liu et al. [109], digestible carbohydrates were 
reduced (54% reduced sucrose and corn starch) in order to maintain an isocaloric diet 
compared to the normoproteic diet. Therefore, in the current experimental designs for 
these studies, it is difficult to identify the critical dietary factor (i.e. change in protein or 
carbohydrate or fat content) that is predominantly controlling the observed 
compositional shift in specific bacterial groups. In any case, decreased relative 
percentages of carbohydrates found in the HP diets likely contributed to reductions of 
many bacterial groups, particularly known fiber-fermenting bacteria such as Roseburia 
and Eubacterium, in several studies [28, 110].   
It is important to note that most of the current studies examining changes in the 
microbiota via a HPD have only examined selected bacterial groups using techniques 
such as FISH and qPCR with group-specific (i.e. class, genera or species) probes [28, 
109, 110], leaving much of the microbial diversity unexplored in these studies. Liu et 
al., (2014) further used DGGE to partially examine changes in the dominant microbial 
groups under HPDs, while Walker et al. [7] is the only known study to investigate the 
microbial community in a controlled HP diet intervention using 16S rRNA gene clone 
libraries. Therefore, there is a current need for more studies employing next-generation 
sequencing techniques (16S rRNA gene amplicon and metagenomic studies) to analyze 
the entire microbial composition changes under the effects of increased dietary protein. 
 
 
3.3. Dietary protein effect on gut microbiota metabolites and host physiology  
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3.3.1. Bacterial metabolites from protein fermentation 
Bacterial metabolites produced from protein fermentation after elevated 
consumption of protein are abundant and diverse, including hydrogen sulfide (H2S), 
ammonia, aromatic compounds (phenol, p-cresol, indole), polyamines (agmatine, 
putrescine, spermidine, spermine, cadaverine), SCFAs, branched-chain fatty acids 
(isobutyrate, 2-methylbutyrate), organic acids (formate, lactate, succinate), ethanol, 
gases (H2, CO2, CH4), and compounds with potential neuroactive activity (GABA, 
serotonin, histamine, L-DOPA, tryamine, nitric oxide, tryptamine, phenethylamine) 
among others [101]. Although much work has been conducted analyzing the 
physiological impacts that these compounds elicit on the host during high protein 
fermentation (reviewed in [111]), many studies have not included an examination of the 
gut microbiota nor have they provided a direct link of microbiota-derived metabolites 
from protein fermentation to the observed physiological effects in the host. 
Metabolomic studies are attempting to establish associations between controlled dietary 
regimens and microbially-produced metabolites in an effort to investigate the role of 
dietary interventions on the microbial metabolome and its subsequent effect on host 
health [112].  However, difficulties in attributing bacterially-derived versus host-derived 
metabolites confound many of these associations, as numerous genetic pathways for 
amino acid metabolism are conserved across bacteria and mammals [113]. On the other 
hand, some gut microbe-specific metabolic products, such as phenolic and indolic 
compounds (phenol, phenylacetate, phenylpropionate, indole, idoleacetate, 
indolepropionate, p-cresol) [114], can be easily traced in host systems. The following 
sections briefly discuss the current knowledge of positive and negative impacts of HP 
diets on host physiology and the possible role that bacterial metabolites generated from 
increased protein fermentation can play in these associated changes.  
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3.3.2. Beneficial effects of dietary protein on host health 
 HP diets are well-known diets used for body weight reduction and are 
considered to be possible strategies for preventing or mitigating weight gain and 
obesity. Many studies analyzing the physiological impact of these diets in humans and 
rodents have found that HP diets reduce body weight, blood pressure, triglyceride levels 
and fat mass, as well as improve cardiometabolic risk factors (reviewed in [115-117]). 
These beneficial effects on host health have been partially attributed to alterations in 
energy metabolism and decreased appetite, which ultimately lead to a reduction in 
energy assimilation and therefore weight loss [118].  Increased energy expenditure has 
been observed after consumption of acute HP diets, presumably due to increases in 
postprandial thermogenesis and resting metabolism [115].  
So far, a direct link between bacterial metabolites and beneficial changes in the 
host physiology is lacking, although current evidence strongly supports possible 
associations. For instance, several amino acid-derived compounds that can be produced 
only by gut bacteria (indole) or by gut bacteria and mammalian host (tyramine, 
tryptamine and SCFAs) have direct or indirect impacts on satiety and gut motility in 
mammals via effects on the incretin GLP-1 and serotonin secretion from 
enteroendocrine cells [119-121]. Furthermore, recent work on the impact of gut 
microbiota on the host central nervous system suggests that several microbial amino 
acid-fermented metabolites (i.e. GABA, serotonin, histamine, L-DOPA, tryamine, nitric 
oxide, tryptamine) may be neuroactive compounds that can produce substantial effects 
in the host, such as regulation of anxiety, mood, cognition, satiety, and immunity 
(reviewed in [121-123]). However, the physiological effect (if any) on the host 
intestinal and periphery tissues of the majority of these compounds is still not well 
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understood.  In addition, the distinction between human- and bacterial-origins of many 
of these compounds has not been well established yet, and further work with in vivo 
studies is necessary to validate such effects. 
 
3.3.3. Adverse effects of dietary protein on host health 
High protein consumption and increased protein fermentation have been linked 
to several important bowel diseases such as colorectal cancer (CRC) and ulcerative 
colitis (UC), as well as impaired renal and mucosal function (reviewed in [6]). Evidence 
for the link between protein fermentation and CRC and UC stems from production of 
potentially carcinogenic and genotoxic metabolites (sulfides, phenols, polyamines and 
ammonia) during protein fermentation, as well as higher protein fermentation in local 
areas where these bowel diseases frequently occur.  Epidemiological studies have 
further suggested a link of prolonged consumption of red and processed meats to 
increased risks of colorectal cancer (reviewed in [111]).  However most of the support 
for the toxic effects of many of these metabolites is based on in vitro studies, and the 
evidence for a direct role of protein fermentation in the etiology of bowel diseases may 
still not be clear [111].  Recent discovery shows that gut microbial metabolism of the 
amino acid derivative L-carnitine commonly found in red meat yields trimethylamine, 
which is further metabolized to trimethylamine-N-oxide in the liver, which can increase 
atherosclerosis in mice [124]. 
Several metabolites produced by the bacterial fermentation of aromatic amino 
acids have been associated with negatively affecting the intestinal mucosal barrier of the 
host as well as causing DNA damage to gut epithelial cells. Phenol has been 
demonstrated in vitro to increase paracellular permeability and decrease the epithelial 
barrier function of Caco-2 monolayers [125]. HP diets have been shown to increase the 
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bacterial-derived genotoxic metabolite p-cresol in feces, along with concomitant 
increases in DNA damage to rat colonocytes and decreases in the integrity of the 
colonic mucosal barrier [126].  Furthermore the type of protein consumed has been 
demonstrated to affect the level of rat colonocyte DNA damage observed, as casein 
caused higher levels of damage compared to cooked lean red beef [127] and red beef 
was higher than chicken [128]. In contrast, a human intervention study with HP diets 
revealed that fecal water genotoxicity did not correlate with protein fermentation [129]. 
Thus, a clear role of p-cresol produced during increased protein ingestion in humans has 
yet to be established in in vivo studies. 
Increased ingestion of dietary protein can also lead to increases in metabolites 
such as p-cresyl sulfate and indoxyl sulfate that may cause a potentially detrimental 
effect on host kidney function [131]. Sulfide, another metabolite produced by increased 
protein fermentation by sulfate reducing bacteria, has been demonstrated to inhibit 
colonocyte mitochondrial respiration and is genotoxic to colonocytes (reviewed in 
[101]). Although the effects of many bacterial metabolites from protein fermentation 
have been investigated in vitro, further studies, particularly in vivo studies in healthy 
human populations, are necessary to determine the true potential toxicity of many of 
these metabolites and their relationship to increased protein ingestion. 
 
 
4. Future Challenges 
 Correctly identifying specific dietary components that effectively modulate the 
gut microbiota composition and function and lead to a predictable change in host 
physiology is confounded by numerous factors. This includes variability in the different 
diets (i.e. type, relative amount, length of interventional period, etc.) used in different 
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studies, thus making comparisons between studies difficult and yielding no definitive 
conclusions about the effects of a particular dietary compound. Furthermore, 
interindividual differences in the initial resident microbiota, particularly observed in 
human intervention studies, may substantially alter the response of a group of bacteria 
to a given dietary compound, which has not usually been considered. It has been 
observed that diet explains a much larger percentage of variation in mice (60%) 
compared to the same variation in humans (10%) due to the ability to control numerous 
factors (diet, environmental exposures, etc.) in mice compared to humans [130]. 
Therefore, conclusions regarding microbiota changes in mice in response to dietary 
changes need to be carefully weighed when applying them to human studies. 
Limitations inherent to experimental design (i.e. reduction in carbohydrate/fiber content 
at the expense of fat or protein in HF and HP experimental diets, respectively) have also 
precluded the identification of the dietary factor actually responsible for the observed 
changes in gut microbial composition and function. In addition, larger and more tightly 
controlled intervention trials, regarding dietary intakes and other confounding factors 
(e.g. physical activity, medication, etc.) are needed to be able to establish more robust 
cause-effect relationships in specific population groups. There is also a need to study 
both host-microbe interactions as well as microbe-microbe co-metabolic processes in 
order to truly understand what is taking place in the so-called ‘black box’ of the human 
gastrointestinal system. 
Although current 16S rRNA gene amplicon surveys are providing valuable 
information on the bacterial taxonomic groups present in the mammalian gut during 
healthy and diseased states, there is a clear need to move beyond these studies to look at 
changes in functional genes using metagenomic and/or metatranscriptomic tools in 
order to better clarify the role that the gut microbiota plays in altering host physiology 
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and contributing to diet-related diseases. Predictive bioinformatic tools (e.g. PICRUSt) 
may also help to gain insight into the genes potentially present in these different 
ecosystems.  Simultaneously, it is imperative that the functional annotation of many of 
the thousands of gut bacterial genes with unknown function be elucidated. 
Unfortunately, this step requires often long, painstaking work with pure cultures and is 
the obvious bottleneck in all studies employing these molecular techniques. Previous 
reports indicate that a large percentage of human gut bacteria are able to be cultured 
(reviewed in [13]).  However, certain bacterial taxonomic groups may not be able to be 
cultured due to unknown growth factors or growth conditions typically found in the 
human gut that favor their colonization. Improvements in microbial culturing of 
recalcitrant strains as well as better functional characterization of unknown genes from 
commonly isolated gut bacteria are a necessity to advance our current knowledge of the 
role of gut bacteria in diet-related diseases. 
 In summary, a mixture of cutting edge advanced ‘-omics’ techniques, as well as 
new gene discovery strategies applied to gut bacterial strains identified in well-design 
human studies, promises to reveal some of the mystery associated with this complicated 
ecosystem, which could be particularly relevant to improve the management of diet-
related diseases. 
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Table 1:  Summary of recent dietary studies utilizing high fat (HF) diets that describe effects on gut microbiota.  All dietary components are in 
percentages unless stated otherwise. Duration indicates the amount of time the dietary change/intervention was given.  All subjects were adults 
unless specifically stated otherwise. The following is a list of abbreviations for subjects: HH (healthy human); M C57BL / 6NCrl mice (male 
C57BL / 6NCrl mice); Mice RELM (RELMβ KO mice); F C57BL / 6NCrl mice (female C57BL / 6NCrl mice); SD rats (Sprague Dawley rats); 
Fout (Female outbred mice); M SD rats intestinal mucosa (intestinal mucosal samples from male Sprague Dawley rats); M Wist (male Wister 
rats). All samples were derived from fecal samples unless specifically stated otherwise. Methods for profiling are abbreviated as follows: Pyroseq 
(454 pyrosequencing); MiSeq (Illumina); MITChip (Mouse Intestinal Tract microarray chip). 
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Dietary change/ 
intervention 
% dietary component 
(% carb / % prot / % fat) 
Duration 
(weeks) 
Subjects Method for 
profiling 
Effect on microbiota Refs. 
Fat       
Habitual long term diet NA NA HH Pyroseq Protein and animal fat: ↑ Bacteroides Carbohydrates: ↑ Prevotella [10] 
Controlled HF/low-fiber 
and LF/high-fiber diets 
HF/LFiber: 35/ 27 /38 
LF/HFiber: 69 / 18 / 13 1.5 HH Pyroseq Stable enterotype identity [10] 
Animal-based diet vs. 
Plant-based diet NA 0.7 HH MiSeq, qPCR 
Animal: ↑ Alistipes, Bilophila and Bacteroides and ↓ 
Firmicutes (Roseburia, Eubacterium rectale and 
Ruminococcus bromii) 
[9] 
HFD vs. carbohydrate diet 
(CARB) 
HFD: 21 /19 / 60 
CARB diet: 66 / 21 / 23 12 
M C57BL / 
6NCrl mice MiSeq, FISH HFD: ↑Rikenellaceae and ↓ Ruminococcaceae [29] 
HFD vs. chow diet HF diet: 35 / 20 / 45 Chow: 60 / 28 / 12 3 Mice RELM 
qRT-PCR, 
Pyroseq 
HFD: ↑Firmicutes (Clostridiales) and Delta-proteobacteria. 
↓ Bacteroidales. [131] 
HFD 
 
 
Normal chow diet 
26.3/ NA / 34.9 
 
 
61.3 / NA / 5.28 
12 
 
10 
M C57BL / 
6J mice Pyroseq 
HFD: ↑ Firmicutes (Lachnospiraceae, Ruminococcaceae, 
Lactococcus) and Proteobacteria.↓ Bacteroidetes 
 
Chow: Addition of normal chow diet caused the HFD-
induced microbiota taxonomic shifts to revert back to similar 
compositions found in control normal chow diet 
[14] 
High saturated fat diet 
(HFD) 
60% kcal from fat, 34% was 
saturated fat 12 
F C57BL / 
6J mice Pyroseq 
↑ Firmicutes and ↓ Bacteroidetes.  At species level, 
↓ Lactobacillus and ↑ Oscillibacter. [34] 
Purified HFD containing 
palm oil (HF-PO; P/S 0.4) 35 / 20 / 45 8 
M C57Bl / 
6J mice MITChip ↑ Clostridium clusters XI, XVII, and XVIII [30] 
Purified HFD containing 
safflower oil 35 / 20 / 45 8 
M C57Bl / 
6J mice MITChip No significant changes [30] 
Purified HFD containing 
olive oil 35 / 20 / 45 8 
M C57Bl / 
6J mice MITChip No significant changes [30] 
HFD vs. Low-fat diet 
(LFD) 
LFD: 70 / 20 / 10 
 HFD: 35 / 20 / 45 8-12 SD rats qPCR 
HFD: ↑ Bacteroidales and Clostridiales 
In DIO-P (obesity prone) rats: ↑ Enterobacteriales [132] 
HFD vs. chow diet 
(Chow) 
HFD (pelleted): 40 / 17 / 
43 
Modified chow (saturated 
animal fat / condensed 
milk): 38 / 10 / 51 
Control chow: 65 / 21 / 12 
16 SD rats Pyroseq 
HFD:↑ Blautia producta, Morganella morgani, 
Phascolarctobacterium, B. fragilis, Parabacteroides 
distasonis, B. vulgatus  and groups Bacteroidaceae, 
Lachnospiraceae, Enterobacteriaceae, Ruminococcaceae, 
Veillonellaceae, Porphyromonadaceae and 
Erysipelotrichaceae.↓ Lactobacillaceae (Lactobacillus 
intestinalis).  
CD: ↑L. intestinalis 
[133] 
	 47	
 
 
 
 
 
 
 
 
 
 
 
 
HFD not supplemented NA 7 Fout Mice 16S qPCR ↑ Firmicutes and the order Enterobacteriales [134] 
HFD with Oleic acid-
derived compound 
27.5 / 23.5/  34.3 / Fiber 
6.5 7 Fout Mice 16S qPCR 
↓ Clostridium cluster XIVa and Enterobacteriales; 
↑ Bifidobacterium spp. and Bacteroidetes [134] 
HFD with n-3 fatty acids 
(EPA and DHA) 
27.5 / 23.5/  34.3 / Fiber 
6.5 7 Fout Mice 16S qPCR ↑ Firmicutes and the group Lactobacillus [134] 
HFD/Energy diet 55.5 / 14.55 / 30 5.7 
M SD rats 
intestinal 
mucosa 
FISH ↑ Lactobacillus/Enterococcus ↓ Bacteroides/Prevotella [135] 
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Table 2:  Summary of dietary studies utilizing high fiber diets.  All dietary components are in percentages unless stated otherwise. Duration 
indicates the amount of time the dietary change/intervention was given.  All subjects were adults unless specifically stated otherwise. The 
following is a list of abbreviations for subjects: HH (healthy human); A w/MS (Adults with metabolic syndrome); IV (in vitro fecal samples); W 
(women); OW (obese women); H (D & EN) (underwent diarrhea and enteral nutrition); C W (constipated women); Over (overweight); Adoles 
girls (adolescent girls); OM (obese men); OH (obese human). All samples were derived from fecal samples unless specifically stated otherwise.  
Methods for profiling are abbreviated as follows: HITChip (Human Intestinal Tract Chip). 
	 49	
Dietary change/ 
intervention 
% dietary component 
(% carb / % prot / % fat) 
Duration 
(weeks) Subjects 
Method for 
profiling Effect on microbiota Refs. 
Whole grain 
WG wheat 67.8 /11.6 / 2.5 / 11.8 fiber 3 HH FISH ↑ Bifidobacterium, lactobacilli [52] 
Wheat bran (WB) 48 / 14 / 3.5 / 27 fiber 3 HH FISH No significant changes [52] 
Maize-based WG 37.04 g / 2.09 g / 1.95 g 14.2 g fiber 3 HH FISH ↑ Bifidobacterium [136] 
Non-WG 39.09 g / 1.63 / 1.68 / 0.81 g fiber 3 HH FISH No significant changes [136] 
WG barley 64.6 / 18.2 / 6.7 / 31.1 fiber 4 HH Pyroseq ↑ Blautia; Slight ↑ in Roseburia, Bifidobacterium, Dialister [55] 
Brown rice 80 / 8 / 3 / 7.3 fiber 4 HH Pyroseq ↑ Blautia [55] 
WG rye bread (RB) 46 / 19 / 33 / 7-15 fiber 12 A w/MS  HITChip No differences observed between groups [54] 
Amylase-pretreated 
wheat bran NA 
72 h at  
37 °C IV / HH Pyroseq 
↑ Eubacterium xylanophilum, Butyrivibrio spp. and 
Roseburia spp. (Lachnospiraceae). ↑ in butyrate-producers 
Firmicutes 
[53] 
Fructans (FOS and inulin)
Inulin Inulin or placebo 3 times/d (20 g/d) 4 
W with low 
iron levels qPCR ↑ bifidobacteria [61] 
Inulin + FOS 
Fiber: 50% inulin and 50% 
fructo-oligosaccharide. 
Placebo: maltodextrin (6g) 
4.1 W receiving radiotherapy FISH ↑ Lactobacillus and Bifidobacterium [60] 
Formula milk + inulin 
+ oligofructose 
0.8 g/dL Orafti(®)Synergy1 
(oligofructose-enriched 
inulin) supplemented infant 
formula 
First 16 
weeks of 
life 
Infants qPCR Similar to microbiota of breastfed infants [62] 
Oligofructose/inulin 
fiber 
7 g/d of oligofructose/inulin 
or placebo (maltodextrin) 1 H (D & EN) FISH 
Non-bifidogenic effect. ↓ Faecalibacterium prautsnizii and 
Bacteroides/Prevotella  [65] 
Long-chain fructans / 
Short-chain fructans 
Agave fructans with diff. 
degree of polymerization 
(DP) profiles. 5 g/kg b.w. 
12 days O mice qPCR Long-chain fructans: ↑ Bifidobacterium. Short-chain fructans: no bifidogenic effect [137] 
Agave inulin 0, 5.0, or 7.5 g agave inulin/d 3 HH MiSeq 
↑ B. adolescentis, B. breve, B. longum, B. pseudolongum. ↑ 
Faecalibacterium. ↓ Desulfovibrio. [67] 
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Inulin/partially 
hydrolyzed guargum 
mixture (I-PHGG) 
15 g/d I-PHGG (fiber group) 
or maltodextrin (placebo 
group) 
3 C W qPCR ↓ Clostridium sp. [138] 
XOS, Inulin + XOS 
and maltodextrin 
(placebo) 
5 g XOS, INU-XOS (3+1 g) 
or equivalent weight of 
placebo 
4 HH qPCR XOS: ↑ Bifidobacterium [139] 
Inulin + oligofructose 
Inulin/oligofructose 50/50 
mix or placebo 
(maltodextrin) 16 g/day 
12 OW Microarray, qPCR 
↑Bifidobacterium and Faecalibacterium prausnitzii. ↓ 
Bacteroides intestinalis, Bacteroides vulgatus and 
Propionibacterium [140] 
Pea fiber + FOS Formulated diets devoid or suppl with fiber (14 g/l) 2 HH FISH 
↑ bifidobacteria in fiber diet. ↓ Faecalibacterium 
prausnitzii and Roseburia intestinalis in both 
supplemented and fiber-free diet 
[141] 
Jerusalem artichoke 
inulin (JA) 
55% inulin, 0.5% glucose, 
2% fructose, 
14% sucrose, 25% water, 
3% minerals 
3 HH FISH 
↑ bifidobacteria. ↓ Bacteroides/Prevotella, 
Clostridium histolyticum/C. lituseburense  
and Clostridium coccoides/Eubacterium rectale. 
[142] 
Chicory inulin (CH) 
88% inulin, max. 10% free 
sugars and max. 0.3% 
minerals 
3 HH FISH 
↑ bifidobacteria. ↓ Bacteroides/Prevotella, 
Clostridium histolyticum/C. lituseburense 
and Clostridium coccoides/Eubacterium rectale. ↑ 
Enterobacteriaceae 
[142] 
Inulin-oligofructose (5 
g/day, twice) 
Beneo; DKSH/Orafti Great 
Britain Ltd, Kent, UK 3 HH 
qPCR, 16S clone 
libraries No significant changes [59] 
Inulin and apple 
pectin  NA 1.7 
IV / HH 
 MiSeq, qPCR 
↑ Bacteroides, Eubacterium eligens, F. prausnitzii. ↓ 
Bacteroides spp. [143] 
GOS 
Trans-GOS mixture 5.5 g/d 12 Over H FISH, ELISA ↑ bifidobacteria, ↓ Clostridium histolyticum, Desulfovibrio, Bacteroides spp. [68] 
GOS twice a day 0, 2.5 or 5 g GOS 3 Adoles girls DGGE and qPCR ↑ Bifidobacterium [144] 
GOS supplemented 
formula milk 
Suppl GOS (0.4 g/100 mL) 
formula 
From 
day 15 of 
life 
Infants qPCR ↑ Bifidobacterium, Lactobacillus and ↓ Clostridium [63] 
GOS Four increasing dosages: 0, 2.5, 5, and 10 g of GOS 12 HH Pyroseq 
↑ bifidobacteria. ↑ Firmicutes (some individuals).       ↓ 
Bacteroides [56] 
Resistant starch 
	 51	
RS (RS2) Hi-Maize 260 (55.72 g/100g) 3 HH 
Pyroseq, DGGE, 
qPCR ↑ Ruminococcus bromii and Eubacterium rectale [72] 
RS (RS4) 
Fibersym (39.33 g/100g), 
water (18.36 g/100g), 
Midsol 50 native starch 
(16.39 g/100g) 
3 HH Pyoseq, DGGE, qPCR 
↑ Actinobateria and Bacteroidetes. ↓ Firmicutes.  
↑ Bifidobacterium adolescentis and Parabacteroides 
distasonis. 
[72] 
RS (RS3) 
434.1 g / 108.8 g / 126.5 g / 
275.5 g starch / 25.56 g 
resistant starch 
3 OM 16S clone libraries, qPCR, DGGE 
↑ Ruminococcus bromii, Eubacterium rectale, Roseburia 
spp., Oscillibacter. [7] 
NSP (wheat bran) 427.3 g / 101.9 g / 135.9 g / 138.3 g starch / 2.33 g RS 3 OM 
16S clone libraries, 
qPCR, DGGE No significant changes [7] 
RS vs non-starch 
polysaccharides  
52 / 13 / 35 /  
combined with 28 g RS or 
non-starch polysaccharides  
3 OH 
Phylogenetic 
microarray and 
qPCR 
↑ Ruminococcaceae and ↑ Lachnospiraceae (respectively) [130] 
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Table 3:  Summary of dietary studies utilizing high protein (HP) diets.  All dietary components are in percentages unless stated otherwise. 
Duration indicates the amount of time the dietary change/intervention was given.  All subjects were adults unless specifically stated otherwise. 
The following is a list of abbreviations for subjects: Wist (Wister rats); OM (obese men); OH (obese human). All samples were derived from 
fecal samples unless specifically stated otherwise. 
Dietary change/ 
intervention 
% dietary component 
(% carb / % prot / % fat) 
Duration 
(weeks) Subjects 
Method for 
profiling Effect on microbiota Refs. 
Protein 
Hyperproteic-hypoglucidic 
isocaloric diet (HP); CH2O not specified or controlled 
(HP) 53% whole milk 
protein with 54% 
reduced sucrose and corn 
starch 
2.1 
Cecal & 
colonic 
content/ Wist 
M rats 
qPCR, DGGE 
↓ Clostridium coccoides, C. leptum, Faecalibacterium 
prausnitzii in cecum and colon. Microbiota diversity higher 
in cecum but lower in colon. 
[109] 
Normoproteic diet (NP) (NP) 14% whole milk protein 2.1 
Cecal & 
colonic 
content/ Wist 
M rats 
qPCR, DGGE No significant changes [109] 
HP and moderate-
carbohydrate (HPMC) diet 181 / 139 g / 82 g 4 OM FISH No significant changes [110] 
HP and low-carbohydrate 
(HPLC) diet 22 g / 137 g / 143 g 4 OM FISH 
↓ Roseburia, Eubacterium rectale, Bacteroides spp. No 
changes in Faecalibacterium prausnitzii. [110] 
HP/Reduced carbohydrate 
weight loss diet NA 3 OM 
SSeq of 16S 
clone libraries, 
qPCR, DGGE 
↓ Collinsella aerofaciens, Eubacterium rectale, and 
Roseburia spp. [7] 
HP and moderate-
carbohydrate (HPMC) vs HP 
and low-carbohydrate 
(HPLC) diet 
HPMC: 35 / 30 / 35 
HPLC: 4 / 30 / 66 4 OH FISH 
↓ Bifidobacterium, Roseburia spp. and Eubacterium 
rectale. No differences in Bacteroides or other Clostridium 
clusters (XIVa, IX, IV). 
[28] 
 Weight loss (WL) diet (high 
protein-medium 
carbohydrate) 
50 / 35/ 15 3 OH 
Phylogenetic 
microarray and 
qPCR 
↓ bifidobacteria [130] 
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